ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 134 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q4 2023. The put-call ratio across all filers is 1.63 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $3,223,380 | +45.0% | 346,600 | +54.5% | 0.34% | +38.2% |
| Q1 2024 | $2,222,813 | +1198.4% | 224,300 | +323.2% | 0.25% | +1130.0% |
| Q4 2023 | $171,190 | -62.9% | 53,000 | -39.1% | 0.02% | -65.5% |
| Q3 2023 | $461,970 | -68.5% | 87,000 | -43.5% | 0.06% | -34.8% |
| Q2 2023 | $1,467,620 | +109.1% | 154,000 | +141.4% | 0.09% | -1.1% |
| Q1 2023 | $701,800 | +8.3% | 63,800 | +45.7% | 0.09% | -1.1% |
| Q4 2022 | $648,240 | -99.9% | 43,800 | -6.4% | 0.09% | -29.5% |
| Q3 2022 | $894,348,000 | +99.8% | 46,800 | +122.9% | 0.13% | +111.5% |
| Q2 2022 | $447,510,000 | – | 21,000 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $305,003,000 | 24.46% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $115,121,000 | 6.52% |
| Pivotal bioVenture Partners Investment Advisor LLC | 569,041 | $16,462,000 | 5.28% |
| SECTORAL ASSET MANAGEMENT INC | 878,948 | $25,428,000 | 1.93% |
| Omega Fund Management, LLC | 623,836 | $18,048,000 | 1.71% |
| Orbimed Advisors | 6,073,850 | $175,716,000 | 1.64% |
| Altium Capital Management LP | 113,962 | $3,297,000 | 0.92% |
| Vivo Capital, LLC | 744,370 | $21,535,000 | 0.76% |
| Polar Capital Holdings Plc | 1,557,543 | $45,060,000 | 0.28% |
| Birchview Capital, LP | 9,000 | $260,000 | 0.15% |